Cargando…

Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections

Tigecycline was previously considered to have activity against vancomycin-resistant Enterococcus (VRE) isolates, but the optimal dose was not clarified. Thus, this study assessed the in vitro activity of tigecycline against clinical VRE isolates to determine its optimal regimens for complicated intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santimaleeworagun, Wichai, Hemapanpairoa, Jatapat, Changpradub, Dhitiwat, Thunyaharn, Sudaluck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533206/ https://www.ncbi.nlm.nih.gov/pubmed/32989939 http://dx.doi.org/10.3947/ic.2020.52.3.345

Ejemplares similares

Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2021)

Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2019)

Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2019)

Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2021)

Clinical Impact of Vancomycin Treatment in Ampicillin-Susceptible Enterococci Bloodstream Infections
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2022)

Is Early Monitoring Better? Impact of Early Vancomycin Exposure on Treatment Outcomes and Nephrotoxicity in Patients with Methicillin-Resistant Staphylococcus aureus Infections
por: Chattaweelarp, Thanawat, et al.
Publicado: (2020)

2284. Treatment and Clinical Outcomes Among Infected Patients with Colistin-resistant Klebsiella pneumoniae Bacteremia.
por: Prawang, Abhisit, et al.
Publicado: (2019)

Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
por: Saelim, Weerayuth, et al.
Publicado: (2021)

The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates
por: Nulsopapon, Parnrada, et al.
Publicado: (2021)

Correction: Nulsopapon et al. The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates. Antibiotics 2021, 10, 736
por: Nulsopapon, Parnrada, et al.
Publicado: (2022)

In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital
por: Lertsrisatit, Yongyut, et al.
Publicado: (2017)

Antimicrobials as Single and Combination Therapy for Colistin-Resistant Pseudomonas aeruginosa at a University Hospital in Thailand
por: Pungcharoenkijkul, Supanun, et al.
Publicado: (2020)

Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting
por: Pongchaidecha, Manat, et al.
Publicado: (2020)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital
por: Nasomsong, Worapong, et al.
Publicado: (2021)

Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections
por: Townsend, Mary L, et al.
Publicado: (2007)

First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience
por: Nasomsong, Worapong, et al.
Publicado: (2021)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

Vancomycin-resistant enterococci: eradication using vancomycin?
por: Van Prehn, J, et al.
Publicado: (2014)

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
por: Eckmann, Christian, et al.
Publicado: (2010)

Emergence of vancomycin-resistant enterococci.
por: Rice, L B
Publicado: (2001)

Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci
por: Kara, Ahu, et al.
Publicado: (2014)

Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin
por: Shlezinger, Mor, et al.
Publicado: (2019)

Nosocomial Infection with Vancomycin-dependent Enterococci
por: Tambyah, Paul A., et al.
Publicado: (2004)

Vancomycin-resistant Enterococci, Mexico City
por: Cuellar-Rodríguez, Jennifer, et al.
Publicado: (2007)

Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline
por: Reygaert, Wanda C
Publicado: (2010)

Intra-abdominal infection after tumor surgery: tigecycline combined with β-lactam antibiotics versus tigecycline alone
por: Cai, Xinfeng, et al.
Publicado: (2023)

Molecular Characterization of Virulence Genes in Vancomycin-Resistant and Vancomycin-Sensitive Enterococci
por: Biswas, Priyanka Paul, et al.
Publicado: (2016)

Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci
por: Mühlberg, Eric, et al.
Publicado: (2020)

Fecal colonization with vancomycin-resistant enterococci in Australia.
por: Padiglione, A A, et al.
Publicado: (2000)

Involving ornithologists in the surveillance of vancomycin-resistant enterococci.
por: Sellin, M, et al.
Publicado: (2000)

Excretion of Vancomycin-Resistant Enterococci by Wild Mammals
por: Mallon, David J. P., et al.
Publicado: (2002)

Experience report on surveillance of vancomycin-resistant enterococci
por: Baraldi, MM, et al.
Publicado: (2011)

Genotyping of Vancomycin Resistant Enterococci in Arak Hospitals
por: Hoseini Zadeh, Adeleh, et al.
Publicado: (2015)

Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci
por: Baëtz, Benjamin, et al.
Publicado: (2021)

In vitro efficacy of vancomycin combined with fosfomycin against Vancomycin-Resistant Enterococci strains
por: Aktas, Gulseren
Publicado: (2020)

1955. Novel Compound Reverses Vancomycin Resistance in Vancomycin-resistant Enterococci (VRE)
por: Onyedibe, Kenneth, et al.
Publicado: (2019)

Intra-abdominal Infections: The Role of Anaerobes, Enterococci, Fungi, and Multidrug-Resistant Organisms
por: Marcus, Gil, et al.
Publicado: (2016)

Vancomycin-Resistant Enterococci, Point Barrow, Alaska, USA
por: Drobni, Mirva, et al.
Publicado: (2009)

Characterizing Vancomycin-resistant Enterococci in Neonatal Intensive Care
por: Sherer, C. Rebecca, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_72c78b8up0mmt3tip2h716rlos